<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200708048062N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-08-10</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>The effect of oxycodone on limb fracture pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of morphine and oxycodone on pain in patients with limb fractures</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-08-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>92</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/50173</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 92 patients were divided into two completely equal groups using morphine and oxycodone using block randomization method. Block randomization method with quadratic block size was used to divide patients into two groups. In this way, using online software (sealedenvelope), the randomization sequence was generated in a block method and remained with the epidemiologist. Following patient diagnosis and based on the generated randomization sequence, a decision was made to assign individuals to groups, Blinding description: Due to the two-sided blindness of the study, in this study, only the relevant specialist in charge of the study (Dr. Solhi, Dr. Azami) is aware of the type of study and the study groups, while patients are of the prescribed drug type. They are not aware. Also, the intern in charge of the project who is in charge of filling out the checklists is not aware of the type of groups based on the prescription drug and only recognizes the groups based on A and B and fills out the checklists accordingly. In the first group, 46 patients receive injectable morphine and placebo, and in the second group, 46 patients receive oral oxycodone and injectable placebo. Receiving the drug after surgery and immediately after transferring the patient to the ward by the responsible intern will be based on group A and B drugs (previously prepared by the main executor of the project) and without mentioning the name of the drug.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Tibial fracture. Condition 2: Tibial fracture. Condition 3: Tibial fracture. Condition 4: Femoral bone fracture.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: 46 patients with lower limb fractures (femur and tibia) immediately after surgery and transferred to the inpatient department of morphine sulfate 5 mg intravenously and 2 oral placebo tablets at the same time to control pain Patients with a VAS score above 5 will be treated according to the standard protocol and excluded from the study, and their number will be recorded in the study. Patients were also evaluated for blood pressure and respiratory level and in case of hypotension, bradycardia, decreased respiratory level and bone fractures will be excluded from the study and their number will be recorded in the study. Intervention 2: Intervention group2: 46 patients with lower limb fractures (femur and tibia) Immediately after surgery and transfer to the hospital ward once, 2 oxycodone 5 mg tablets simultaneously and orally and intravenously injectable placebo to control pain Patients with a VAS score above 5 will be treated according to the standard protocol and excluded from the study, and their number will be recorded in the study. Patients were also evaluated for blood pressure and respiratory level and in case of hypotension, bradycardia, decreased respiratory level and bone fractures will be excluded from the study and their number will be recorded in the study.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Pouria Rezae</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar-e-azam Complex, Basij Sq., Sardasht Town</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3848176341</zip>
        <telephone>+98 86 3417 3639</telephone>
        <email>research@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Pouria Rezae</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar-e-azam Complex, Basij Sq., Sardasht Town</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3848176341</zip>
        <telephone>+98 86 3417 3639</telephone>
        <email>research@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients whose bone fractures of the lower extremity (tibia and femur) are confirmed by graphic and are candidates for analgesia after surgical treatment.
Age between 18 to 60 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>opioid addiction
hypotension, bradycardia, or decreased respiratory rate.
history of diabetes and kidney failure.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S82.1</hc_code>
      <hc_code>S82.2</hc_code>
      <hc_code>S82.3</hc_code>
      <hc_code>S72</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of upper end of tibia</hc_keyword>
      <hc_keyword>Fracture of shaft of tibia</hc_keyword>
      <hc_keyword>Fracture of lower end of tibia</hc_keyword>
      <hc_keyword>Fracture of femur</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: 46 patients with lower limb fractures (femur and tibia) immediately after surgery and transferred to the inpatient department of morphine sulfate 5 mg intravenously and 2 oral placebo tablets at the same time to control pain Patients with a VAS score above 5 will be treated according to the standard protocol and excluded from the study, and their number will be recorded in the study. Patients were also evaluated for blood pressure and respiratory level and in case of hypotension, bradycardia, decreased respiratory level and bone fractures will be excluded from the study and their number will be recorded in the study.</i_keyword>
      <i_keyword>Intervention group2: 46 patients with lower limb fractures (femur and tibia) Immediately after surgery and transfer to the hospital ward once, 2 oxycodone 5 mg tablets simultaneously and orally and intravenously injectable placebo to control pain Patients with a VAS score above 5 will be treated according to the standard protocol and excluded from the study, and their number will be recorded in the study. Patients were also evaluated for blood pressure and respiratory level and in case of hypotension, bradycardia, decreased respiratory level and bone fractures will be excluded from the study and their number will be recorded in the study.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intensity of pain. Timepoint: Before the intervention and 30 minutes, 2 hours and 6 hours after the intervention. Method of measurement: Visual Analogue Scale of Pain.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-07-12</approval_date>
        <contact_name>Ethics committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Payambar-e-azam Complex, Basij Sq., Sardasht Town Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
